Vol 31, No 2 (2024)
Letter to the Editor
Published online: 2024-04-26

open access

Page views 216
Article views/downloads 132
Get Citation

Connect on Social Media

Connect on Social Media

Lipoprotein(a): an important consideration for DAPT therapy after PCI

Kongyong Cui123, Kefei Dou123
Pubmed: 38686991
Cardiol J 2024;31(2):365-366.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Cui K, Wu S, Yin D, et al. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiol J. 2024; 31(1): 32–44.
  2. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998; 18(9): 1393–1399.
  3. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007; 13(9): 1086–1095.
  4. Tsironis LD, Mitsios JV, Milionis HJ, et al. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004; 63(1): 130–138.
  5. Barre DE. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res. 2007; 119(5): 601–607.
  6. Zhu P, Tang XF, Song Y, et al. Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention. Platelets. 2021; 32(5): 684–689.
  7. Kubica J, Adamski P, Gorog D, et al. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal. 2022; 29(1): 148–153.